Professional Documents
Culture Documents
Journal of Liposome Research - 2021 Dec (광고심의 근거 자료) ★
Journal of Liposome Research - 2021 Dec (광고심의 근거 자료) ★
To cite this article: Sreerag Gopi & Preetha Balakrishnan (2020): Evaluation and Clinical
Comparison Studies on Liposomal and Non-Liposomal Ascorbic Acid (Vitamin�C) and their
Enhanced Bioavailability, Journal of Liposome Research, DOI: 10.1080/08982104.2020.1820521
t
ip
a
Centre for Innovations and Technologies (CIT), ADSO Naturals Private Limited, D436, 14th
cross, Peenya Industrial Area, Peenya 2nd Stage, Bangalore-560058, India
cr
b
Research and Development, Curesupport B.V, Zutphenseweg 55, 7418 AH, Deventer, The
Netherlands
us
KEYWORDS: Vitamin C; Liposomes; Pharmacokinetics; Bioavailability; Nutraceuticals
an
*Corresponding authors:
M
Dr. Sreerag Gopi
Email: [email protected]
Mob.: +91-8594023331
d
Off.: +91-480-2733341
e
Mob.: +91-7025921175
Off.: +91-480-2733341
ce
Ac
Graphical Abstract
The aim of present study was to evaluate the oral bioavailability of liposomal vitamin C and
non-liposomal vitamin C in healthy, adult, human subjects under fasting conditions through
an open label, randomized, single dose, two-treatment, two sequence, two-period, two way
crossover, study. The vitamin C loaded liposome was well characterized using transmission
electron microscopy (TEM), dynamic light scattering (DLS) and zeta potential measurements
t
ip
for evaluating morphology, particle size and stabilities, respectively. Microscopic image
shows the core type structure which confirms the characteristic pattern of liposome. The
cr
encapsulation efficiency (EE%) and the particle size were 65.85± 1.84% and below 100 nm
us
respectively. The results of the clinical studies of liposomal vitamin C by oral delivery to be
an
1.77 times more bioavailable than non-liposomal vitamin C. The Liposomal Vitamin C
demonstrated higher values of Cmax, AUC0-t and AUC0-∞ related to non-liposomal Vitamin C
M
due to liposomal encapsulation. No adverse events were reported. It could be concluded that,
pattern, uniform particle size and highly efficient which leads to have enhanced
pt
bioavailability.
ce
Ac
Ac
ce
pt
ed
M
an
us
cr
ip
t
1. Introduction
The demands of various food and nutraceutical industries seek to develop products
with high nutritional value by the fortification of vitamins with the aim to improve
physiological function and to provide health benefits. One of the main vitamins used for this
widely applied in food. It is used, next to its properties as an essential vitamin, as an additive
t
ip
primarily due to its reducing and antioxidant properties. The use of ascorbic acid in food is
cr
enzymatic browning, oxygen scavenging, inhibition of nitrosamine formation, etc. The high
us
reactivity of vitamin C and the susceptibility to oxidation can result in fast exhaustion in
an
various food products. The initial concentration of vitamin C sis difficult to sustain during
products shelf life due to its reactive behavior. The speed of degradation of vitamin C is a
M
complex process and depends on many variables such as relative humidity, pH, temperature
etc (Assadpour & Mahdi Jafari, 2019; De Britto et al., 2016; Haham et al., 2012; Katouzian
e d
& Jafari, 2016). Nanoencapsulation technique has been widely used nowadays to enhance
pt
2020) studies the uses chitosan as a nanocarrier to encapsulates active food components.
Recent years, consumers prefer to use nutraceutical supplements that can contribute to
Ac
prevention/healing of various diseases and as an immunity booster. So, researchers all over
the world have studied the bioavailability, efficacy and toxicity of nutraceutical supplements.
Most common form of delivery is orally and it involves various key steps (1) the release of
active nutraceutical ingredients in gastrointestinal fluid, their solubilization and contact with
other gastrointestinal fluids (2) absorption of active nutraceutical ingredients by the epithelial
cells and their biochemical transformation. These steps are endogenous factors that are
several other factors like physicochemical properties of active components, food processing,
Liposomes are vesicles that are simple imitated of highly complex cell membranes,
comprising lipid bilayers surrounding aqueous core, which have fascinated significant
t
ip
attention on delivering and protecting of both hydrophilic and hydrophobic compounds like
cr
liposomes can promote the protection and activity of the vitamin C (Dima et al., 2020)(W.
us
Liu et al., 2017). Liposomes comprised of biocompatible biodegradable material and it
an
consists of aqueous volume entrapped by one or more bilayers of natural/ synthetic lipids
(Sharma & Sharma, 1997; Tiwari et al., 2012). Water insoluble drugs are typically
M
incorporated into the lipid membrane of the liposome and encapsulation is restricted by the
drug-to-lipid mass ratio (Allen & Cullis, 2013; Chonn & Cullis, 1995; Nedovic et al., 2011;
e d
Wijetunge et al., 2020). Further, hydrophobic drugs can interfere with the bilayer structure of
pt
the nanocarrier, leading to liposomal instability and uncontrolled release (Akbarzadeh et al.,
ce
The blend of liposomal formulation of vitamin C with squeezed orange didn't change
Ac
its organoleptic qualities and indicated microbiological solidness after sanitization and
capacity at 4 °C for 37 days (Marsanasco et al., 2011) . A polyelectrolyte delivery system for
sodium alginate onto the surface of anionic nanoliposomes which demonstrated that
liposomes can give a potential platform for tailored design of carriers for nutrients or
preservatives to enhance both the shelf-life and safety of food matrices (W. Liu et al., 2017).
cholesterol (chol) and were promising Vitamin C carriers with a great loading efficiency and
payload with 15 weeks storage over 85% Vitamin C was protected against oxidation (N. Liu
& Park, 2010). Vitamin C (Ascorbic acid) is better considered as a true vitamin because in
humans cannot be able to synthesis it. Vitamin C acts as a reducing agent since it exhibits a
t
ip
number of enzymatic/non-enzymatic effect and its ability to donate electrons. Vitamins also
cr
oxidative damage to DNA, intracellular proteins. In plasma it increases endothelium-
us
dependent vasodilatation and lowers extracellular oxidants from neutrophils. Insufficiency
an
in vitamin C results in the potentially fatal disease scurvy, low invulnerability which can be
cured only by administering right dose of vitamin C (Hemilä & Chalker, 2020; Van der
M
Velden, 2020).
Only few studies were published showing the effect of liposomal encapsulation on the
e d
bio-availability of Vitamin C. Hickey et al (2008), found in a very small study with only two
pt
such as 20 g and 36 g, plasma level of vitamin C resulted in plasma levels higher than ever
Ac
shown before in literature. This result indicates that liposomes might be an excellent carrier
for Vitamin C to achieve higher blood levels of Vitamin C which cannot be reached with
other dosage forms. This is very important for reaching therapeutic plasma levels of Vitamin
C. (Hickey et al., 2008). Davis et al. (2016) evaluated the plasma levels of oral, intravenous
and oral liposomal Vitamin C. The results indicated that liposomal vitamin C have enhanced
bioavailability than non-liposomal vitamin C, while avoiding the risks associated with
intravenous administration (Davis et al., 2016). However, no real bio-availability study for
the absorption of liposomal vitamin C is published (Davis et al., 2016). The aim of this study
is to fill this gap. An open label, randomized, single dose, two-treatment, two sequence, two-
period, two way crossover, oral bioavailability study is shown for liposomal vitamin C
t
ip
subjects under fasting conditions.
cr
2. Materials and methods
us
2.1. Study materials
an
The study products non-liposomal vitamin C (NLVC) and liposomal vitamin C (LVC)
were supplied by CureSupport, Deventer, The Netherlands. Liposomal vitamin C was prepared
M
using the thin-film evaporation method. Sodium ascorbate and phospholipids were mixed in the
d
ratio of about 2:1 (w/w) and mixed with ethanol. The suspension was evaporated by using a
e
rotary evaporator to form a dry slurry after evaporation of the solvent (ethanol) for the
pt
phospholipids. Sodium ascorbate was dissolved as much as possible in water and stirred with the
ce
phospholipid film under high shear mixing. The concentrated suspension was homogenized
under high pressure and diluted till a concentration of 1 g vitamin C per 5 mL. The material was
Ac
sieved through a 0.2 µm filter. The particles lower than 200 nm were used. The end
concentration was 5 g of vitamin C as ascorbic acid and sodium ascorbate per 25 mL. Non-
liposomal vitamin C was prepared using the same steps as mentioned above without
Transmission electron microscopy ((TEM) JEOL-2100 model) was used to establish the
morphology and dimension of LVC. Prior to analysis, dilute suspension of liposomal vitamin C
pasted on a copper grid and dried in the presence of UV lamp. The analysis was carried out with
accelerating voltage of 25 kV. The particle size of LVC was analysed by dynamic light scattering
(DLS) analysis using a Zetasizer Nano ZS (Malvern Instruments Ltd, United Kingdom) device
t
ip
(S. Gopi et al., 2018). A few drops of LVC dispersion pipetted out using a micropipette, then
cr
poured into a quartz cuvette followed by dilution using Milli-Q water. The measurements were
us
conducted at 25 °C and triplicate of each sample was measured in successive runs and in each
run the sample was scanned ten times, allowing one to produce accurate size determination
The surface charge and stability of LVC dispersions were determined by zeta potential
e
measurements, which were conducted on the same instrument such as Zetasizer Nano ZS
pt
(Malvern Instruments Ltd, United Kingdom). The measurements were performed at 25 °C (S.
ce
The supernatant obtained after centrifugation of liposomes was analysed for unentrapped 5FU
using high performance liquid chromatography (HPLC, Waters, India). The experiment
demonstrated out on C18 column at 30OC. The EE% was calculated using equation
Whereas, TD is the amount of vitamin C initially added to the formulation and FD is the amount
of the free vitamin C in the supernatant after centrifugation (Moghimipour et al., 2018b)
t
2.3.1 Ethical approval
ip
The study was commenced after a written approval obtained from the Institutional Ethics
cr
Committee. The experiments were demonstrated based on the ethical guidelines as per the
us
biomedical research on Human Participants, ICMR (2006), ICH (Step 5) 'Guidance on Good
Clinical Practice’, Schedule Y (amended version, 2014) (Bhattacharya & Sur, 2007) of Central
an
Drugs Standard Control Organization (CDSCO), 'Good Laboratory Practice', ‘Good Clinical
M
Practices for Clinical Research in India’ Guidelines, Good Clinical Laboratory Practice (GCLP),
Declaration of Helsinki (Fortaleza, October 2013), 21CFR part 50, 56 and 320-USFDA
e d
This study was an open label, randomized, single dose, two-treatment, two sequence, two-
Ac
period, two-way crossover, oral bioavailability study in healthy, adult, human subjects under
fasting conditions (Tohen et al., 2000). The flow chart of the study design was shown in Fig. 1.
The aim of the analysis was to evaluate the oral bioavailability of liposomal vitamin C
human subjects under fasting conditions and to monitor the adverse events and ensure safety of
The study demonstrated with adult and healthy human beings and all registered subjects
ce
were fulfilled the experiment. The qualified persons (subjects), satisfied the inclusion/exclusion
criteria for the study (Saravanan, 2014), were allocated randomly. Randomization was carried
Ac
out for 24 subjects using SAS® software version 9.4. The duration of this study was 10 days
(from the day of check-in of first period to the last blood sample collection of second period
including a washout period of 7 days. The study was conducted at SPINOS Life Science and
water on Period I and Period II at ambient temperature (the procedure explained elsewhere
(Saravanan, 2014) in a treatment time of one week were administrated to subjects under fasting
conditions (Tippabhotla et al., 2013). Subsequently, the oral cavity of subjects was examined by
qualified personnel. To generate randomization schedule SAS® software (version 9.4) were used
after receiving the test and reference materials. The randomization was adjusted, and the code
t
ip
was held under controlled access (Saravanan, 2014).
cr
2.3.5 Methodology
us
Totally 24 subjects were enrolled in the study. In regular intervals, subjects were housed in
the clinical facility for at least 11 h pre-dose to 24 h post-dose and the washout period of at least
an
7 days from the successive dosing day. In every period, an overnight fasting of at least 10 h, in
M
the beginning of day, a single oral dose, 5 mL of either LVC or NLVC was administered by
using syringe, (as per randomization schedule) after administration of investigational medicinal
d
products, syringe was cleaned with 240 mL of drinking water, at ambient temperature, to the
e
pt
subjects in sitting posture, under the supervision of investigator and trained study personnel
(Jain, n.d.) including quality assurance auditor. Mouth check with the help of tongue depressor to
ce
Totally 21 blood samples were collected including the pre-dose sampling in each period.
For the pre-dose blood sample (0 h) 6 mL was collected within 60 min prior to dosing. Post dose
blood samples 6 ml was collected at 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00,
6.00, 7.00, 8.00, 9.00, 10.00, 11.00, 12.00, 14.00, 16.00 and 24.00 hours. All samples were
collected in pre-labeled K2EDTA– vacutainers from a fore-arm vein using an indwelling cannula
as per the discretion of investigator. Heparin-lock technique was used to prevent clotting of
blood in the indwelling cannula (Sreeraj Gopi et al., 2017). Before the blood sample was drawn
via the indwelling cannula, 0.5 mL of blood was discarded so as to prevent the saline diluted
blood and heparin (10 IU/mL) from interfering with the analysis. Cannula was removed after 24
h sample was drawn or earlier or if blocked. Vacutainers were positioned vertically in a stack
kept in ice bath while centrifugation and during separation. After assortment of blood tests from
t
ip
all the subjects at each time point, the gathered examples were put in a thermo-protected box
containing wet ice and it was moved to the sample preparing room where the blood tests was
cr
centrifuged at 4000 ± 50 rpm for 10 minutes at 2 °C to 8 °C to isolate the plasma. Centrifugation
us
was carried out within 30 min of the collection of samples, at each time-point. The separated
an
plasma was equally transferred to polypropylene tube (previously labeled with study code and
sample code) in two aliquots. These aliquots were stored upright at a temperature of -30 ± 10 °C
M
and -70 ± 15 °C, till the end of the study. At the end of the study, the samples were transferred to
the bioanalytical facility in a thermo-insulated boxes containing sufficient dry ice. Plasma
e d
supplied with standard diet and continuously examined for well-being and safety throughout the
ce
study. Quality assurance audits were conducted at different phases of study to ensure that the
study was performed in accordance with good clinical and laboratory practices and applicable
Ac
regulatory norms.
Subjects who satisfy all of the following conditions were considered for study enrollment,
which are included normal, healthy, adult, male and female subjects of age between year 21-65
with a body mass index (BMI) in between 18.50 kg/m2 to 24.99 kg/m2 (Jude et al., 2018; Lopez-
Toledano et al., 2017; Maki et al., 2018; Saravanan, 2014). Subject agreed avoid vitamin C
containing medicines and dietary supplements from screening until last visit and high activity
physical exercise 72 h prior to last visit. Subjects having no proof on fundamental sickness at the
time of screening followed by registration and their screening is conducted inside 29 days of
check in. The values from the screening lab are inside ordinary cutoff points or considered by the
t
ip
clinical history, physical assessment (including but not limited to assessment of the
cr
imperative sign appraisals. Typically, healthy as documented by 12-lead electrocardiogram
us
(ECG), X-Ray and clinical research center appraisals. Non-smokers or ex-smokers, the ex-
an
smokers are characterized as somebody who has totally quit smoking for at any rate the previous
3 months. Subjects were ready to consume ova-lacto vegetarian diet and to comply with all
M
requirements of this study protocol as well as instructed by the study personnel.
d
The subjects with history or significant presence of the following were excluded from
e
participation/enrollment in the study, which are the indication of allergic reaction or identified
pt
history of liver disease, myasthenia, alcohol abuse, existing tinnitus, renal or liver impairment
and pre-existing gallbladder disease. Any general disease during the previous 3 months or
Ac
several current lasting medical diseases. Any disease or condition which might compromise the
central nervous system, diabetes, psychosis or any other body system. History of liquor addiction
failure, angina pectoris, ventricular arrhythmias or atrial fibrillation with >100/min ventricular
rate. Gastrointestinal bleeding in last three months, uncontrolled diabetes mellitus, active
disorder, lack of cooperation, chronic obstructive lung disease or active smoking (more than 2
cigarettes in the past 6 months), taking more than 100 mg vitamin C daily within 14 days to
screening (Moghimipour et al., 2018b) as per ClinicalTrial.gov (NCT 0012 2184). Consumption
of caffeine and /or xanthine containing products (i.e. coffee, tea, chocolate, and caffeine-
t
ip
containing sodas, colas, etc.), tobacco containing products for at least 24 h prior to check-in and
cr
us
Consumption of grapefruit and its juice and poppy containing foods (Fitzsimmons et al.,
2018) for at least 72 h prior to check-in and throughout the study. Subjects who taken any
an
prescription medications, over the counter medical products, herbal medications within 14 days
prior to study in and throughout the study. History of dehydration from diarrhea, vomiting or any
M
other reason within a period of 24 h prior to study check-in of each period, an unusual or
d
abnormal diet within 48 h prior to study check-in of each period, for whatever reason because of
e
fasting due to religious reasons. Positive results for drugs of abuse (Marijuana-THC,
pt
MOR) in urine and positive results for alcohol breath test prior to check-in of this study period.
Any blood donation or excess blood loss within 90 days of check in, systolic blood pressure less
Ac
than 90 mmHg or more than 140 mmHg and diastolic blood pressure less than 60 mmHg or more
than 90 mmHg. Intake of any kind of hormonal agent at any time within 2 weeks prior to start of
at the end of the investigation and assessment of the adverse events observed during the course
of the study (S. L. Rogers et al., 2000; Saravanan, 2014). All study participants were
continuously monitored by medical personnel during the housing periods. A physician was
available during the study periods. Clinical examinations and vital signs measurements were
done before check-in, before check-out (24.00 h), at pre-dose (0 h), at 01.00, 03.00, 06.00 and
t
ip
12.00 hours after dosing were documented in the case report forms.
cr
2.3.8 Pharmacokinetic evaluation
us
The study was considered to evaluate comparative bioavailability of LVC and NLVC,
consequently pharmacokinetic profile (rate and extent of drug) of both LVC and NLVC products
an
were assessed based on measured concentration of drug in human plasma collected in clinical
M
phase (Saravanan, 2014). The extent of relative oral bioavailability value for AUC0-t was found
using the formula of AUC0-t of LVC / AUC0-t of NLVC. The pharmacokinetic analysis was
d
performed employing the estimated concentration vs. time profiles of Vitamin C using
e
pt
WinNonlin® version 7.0 (Sreeraj Gopi et al., 2017). The parameters, AUC0-t, Cmax and AUC0-∞
were considered as primary pharmacokinetic parameters and tmax, t½, and Kel were considered as
ce
Analysis of variance (ANOVA) consistent with two one-sided test for bioequivalence, ratio
analysis and 90% confidence intervals for ratio of least square mean of Ln-transformed data of
Cmax, AUC0-t and AUC0-∞ for vitamin C were calculated by using SAS® software version 9.4 of
The use of liposome as a nanodrug delivery carrier should satisfy following criteria (1) the
amount of drug encapsulated in liposomes, (2) particle size and (3) stability of liposome
t
ip
(Moghimipour et al., 2018b; Pereira et al., 2016). To better understand the morphology of
cr
us
an
M
e d
pt
ce
Ac
By closely look into the TEM images, we can see that the liposomes are spherical in size and
shape and there was minimal liposomal debris which might be indicative of vesicle rupture
(Cipolla et al., 2014). The encapsulation efficiency of Vitamin C in liposomes are found to be
65.85± 1.84% which was calculated by chromatographic technique. This encapsulation
efficiency indicates that liposome are suitable drug carriers. Liposomes were spherical in
shape (Bochot & Fattal, 2012; Moghimipour et al., 2018a) and are well dispersed as
indicated by the TEM image (Fig. 2). The mean particle size of liposomes was calculated by
image J software and found to be 245.00± 4.58 nm. After conjugation with Vitamin C, the
spherical morphology of liposomes, remain unaltered. It is well known that the size of
t
ip
liposomes is one of main influence for the tissue targeting. Larger liposomes are often taken
up by phagocytes; while, small liposomes (100 to 200 nm) can penetrate easily in tumor
cr
tissue due to higher permeability and retention (EPR) effects (Maione-Silva et al., 2019;
us
Moghimipour et al., 2018a; Nogueira et al., 2015).
being analysed. The principle of DLS is based on scattered light intensity caused by the
e
pt
(Balakrishnan et al., 2018). Fig. 3a shows intensity distribution data of liposomal vitamin C.
ce
The results suggest that maximum intensity of nanoliposomes lies below 100 nm. Usually
Ac
liposomes have higher polydispersity index (PDI) which suggest a heterogenous vesicle
population. The results of particle size measurements by DLS method indicated that
Stability is one of the critical factors to be considered during the formulation and design of
methods and/or long term storage. Gradually this instability results in rapid uptake of drugs
by the epithelial system with subsequent rapid clearance and shorter lifetime. Hence
preparing liposomal nanostructures with uniform size and stable lifetime is one of the
t
ip
cr
us
an
M
d
Fig. 3. (a) DLS (Intensity distribution data of LVC) (b) Zeta potential of LVC.
e
pt
Fig.3b shows zeta potential value of LVC. The zeta potential is calculated based on velocity
ce
and direction of particles under the influence of a known electric field (Pignatello et al.,
Ac
2006). It illustrates the charge of the particles (surface), and used to measure the possible
extent of flocculation and de-flocculation and colloidal stability of nanosuspension (IM &
2003, n.d.). Generally, a large positive or negative value of zeta potential indicates better
particles(Joseph & Singhvi, 2019). Small zeta potential value results in particle aggregation
and flocculation due to van der waals force of attraction exists between them which results in
physical instability of colloidal suspension. In the present study, zeta potential have greater
value (-40 mV) (Hakkimane et al., 2018). This confirms that our formulation on LVC is
from surrounding conditions due to the possibility of more drug reaching the targeted site.
Since LVC are taken up by the cells by a different mechanism called endocytosis and able to
t
ip
release active ingredient ie, vitamin C in a slow, sustained and steady manner inside the
cr
cellular membrane and they can deliver the therapeutic amount of drug to kill the
us
intracellular bacilli (Hakkimane et al., 2018)(J. A. Rogers & Anderson, 1998).
an
M
e d
pt
ce
Ac
To deliver active ingredients the liposome must be circulated inside the body for a
considerable amount of time (Roy et al., 2015). Main mechanism behind the interaction of
active ingredient loaded liposomal structure is Endocytosis. The endosomal lipidic layer
components destabilizes after the entrance of LVC complex into the cells (Fig. 4).
Endosomal liposomal structure gradually diffuses into liposomal complex and form neutral
ion pairs. This eventually release displacement of actives from liposomal structure and
t
ip
All 24 subjects finished both the periods of the study. Their demographic details are
cr
given in Table 1. Their average age, height, body weight and BMI were 33.54 years, 170.25
us
cm, 75.08 kg and 25.86 kg/m2 respectively. Here, one thing to be noted that, all subjects in
the study were Asian. The vital signs of the subjects were comparable throughout the study.
an
There is no oppositional experience reported throughout the course of the analysis.
M
Therefore, it can be assumed that both the LVC and NLVC samples were nontoxic and well
accepted at the selected dose level in the human subjects. The LVC and NLVC products were
d
administrated in a randomized schedule. The main objective of this study was to evaluate the
e
pt
t
ip
cr
us
an
M
e d
pt
Fig. 5. Mean plasma concentration (mg/dL) of vitamin C form LVC compared with
The AUC is one of the consistent measures of the bioavailability which specifies more
accurate value due to the measurement of entire response over time period [comparative
paper]. The maximum plasma vitamin C (Cmax) and AUC0-t for the LVC were 5,2 mg/dL and
55,9 mg/dL respectively, whereas for the NLVC were 2,2 mg/dL and 31,5 mg/dL. The
extent of the relative oral bioavailability of vitamin C was found higher for LVC than NLVC,
t
ip
which is indicated that the LVC was shown 1.77 times more bioavailable than the NLVC and
cr
2.41 times better considering of the rate of absorption.
us
A significant difference (P < 0.0001) was observed between LVC and NLVC products
due to the treatment effect for the pharmacokinetic primary parameters Cmax, AUC0-t, AUC0-∞
an
(Nazarudheen et al., 2013), but there was no significant difference between LVC and NLVC
M
products in the sequence and period effect (Table 3).
d
Table 3. Statistical results of LVCC versus NLVCC for vitamin C as ascorbic acid
The first bioavailability study of vitamin C was reported by Hickey et al. in 2008.
Hickey et al. proved that there is no difference in absorption between 5 g liposomal vitamin
C as compared to 5 g of non-liposomal vitamin C in commercial tablets. It needs to be
remarked that Hickey used tablets with Bioflavonoids which might influence absorption of
Vitamin C. Hickey also showed that the consumption of 20 and 30 g of liposomal vitamin C
registered remarkable increase in plasma levels of vitamin C which were not shown in
literature before, (Hickey et al., 2008). From this study it can be concluded that there is an
advantage in using the more expensive liposomal vitamin C compared to tablets only in the
t
ip
high dosages (> 5 grs). Juan Manuel Serrano Nunez (2014) showed a significant
bioavailability of vitamin C in rats for liposomal sodium ascorbate as compared with non-
cr
liposomal sodium ascorbate (Sánchez-Lara et al., 2014). Davis et al. (2016) demonstrated
us
more bioavailability of vitamin C by oral consumption of equivalent to 4 g of vitamin C,
an
when delivered through liposomes compared with un-encapsulated vitamin C. In spite of
than normal oral intake (Liposomal Vitamin C obtained from LivonLabs; personal
e d
contain different amounts of vitamin C (Sreeraj Gopi et al., 2017), having different
see that the data found in literature differ so widely. These differences are illustrated in Table
4 which summarizes published pharmacokinetic data from studies with vitamin C (Davis et
al., 2016; Sreeraj Gopi et al., 2017; Hickey et al., 2008) and different liposomal vitamin C
formulations used by Hickey et al (Hickey et al., 2008) Davis et al (Davis et al., 2016) and
t
et al., 2008)
ip
5000 4.3 (245 mM/L) 8.6 Hickey et al. 2008 (Hickey
et al., 2008)
cr
4000 3.2 (228 mM/L) 8.0 Davis et al. 2016 (Davis et
us
al., 2016)
Table 4. Pharmacokinetic properties of various vitamin C combinations expressed per mg
an
The above data were compared based on Cmax per mg vitamin C administrated. The
average Cmax per mg vitamin of the LVC product as compared with the averages of
M
unformulated vitamin C reported by Levine et al. (Gill et al., 1995) and Hickey et al. (Hickey
d
et al., 2008), the values of LVC were about 4 and 6 fold greater respectively. When one
e
makes this comparison between the LVC with the value found by Hickey, the Cmax per mg
pt
vitamin C for the LVC study product is approximately 6-fold greater. A similar comparison
ce
with the data found by Davis et al (Davis et al., 2016) indicates that the Cmax per mg vitamin
C for the LVC product was approximately 6.6 fold greater which is shown in table 4. In this
Ac
study, even though the subjects were consumed 1 g equivalent vitamin C the bioavailable
difference were greater, remarkable and more striking. At this point it is not possible explain
these differences. It might be the differences in the pharmacokinetics of the volunteers in the
different studies, the dissimilarities in the analytical procedures followed to measure plasma
encapsulation is absolute a promising route for the increase in the clinical effectiveness of
oral ascorbic acid. However, more study is required to obtain reliable formulations and
4. Conclusions
t
ip
In summary, this study was an open label, randomized, single dose, two-treatment, two
cr
sequence, two-period, two way crossover, oral bioavailability study of Vitamin C
us
encapsulated in liposomes in healthy, adult, human subjects under fasting conditions.
Microscopic image shows the core type structure which confirms the characteristic pattern of
an
liposome. After conjugation with Vitamin C, the spherical morphology of liposomes, remain
M
unaltered. The encapsulation efficiency (EE%) and the particle size were 65.85± 1.84% and
below 100 nm respectively. The results of the clinical study indicate that the oral delivery of
d
vitamin C encapsulated in liposomes registered 1.77 times more bioavailable than the non-
e
pt
normalization of the data on the basis of Cmax per mg administrated vitamin C indicates that
Ac
Acknowledgement
The authors gratefully thank the management and laboratory members of ADSO naturals (P)
Ltd, Bangalore and Curesupport Netherlands for their active support and cooperation. We
would also like to thank Prof. Sabu Thomas, Mahatma Gandhi University Kottayam for his
References
t
Akbari-Alavijeh, S., Shaddel, R., & Jafari, S. M. (2020). Encapsulation of food bioactives and
ip
nutraceuticals by various chitosan-based nanocarriers. In Food Hydrocolloids (Vol. 105, p.
cr
105774). Elsevier B.V. https://doi.org/10.1016/j.foodhyd.2020.105774
us
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y.,
an
Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013). Liposome: Classification, preparation,
Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical
e
applications. In Advanced Drug Delivery Reviews (Vol. 65, Issue 1, pp. 36–48). Elsevier.
pt
https://doi.org/10.1016/j.addr.2012.09.037
ce
Assadpour, E., & Mahdi Jafari, S. (2019). A systematic review on nanoencapsulation of food
Ac
Food Science and Nutrition (Vol. 59, Issue 19, pp. 3129–3151). Taylor and Francis Inc.
https://doi.org/10.1080/10408398.2018.1484687
Balakrishnan, P., Gopi, S., Sreekala, M. S., & Thomas, S. (2018). UV resistant transparent
Bhattacharya, S. K., & Sur, D. (2007). Ethical guidelines for biomedical research on human
https://go.gale.com/ps/i.do?p=HRCA&sw=w&issn=09715916&v=2.1&it=r&id=GALE%7
CA175876379&sid=googleScholar&linkaccess=fulltext
t
Bochot, A., & Fattal, E. (2012). Liposomes for intravitreal drug delivery: A state of the art. In
ip
Journal of Controlled Release (Vol. 161, Issue 2, pp. 628–634). Elsevier.
cr
https://doi.org/10.1016/j.jconrel.2012.01.019
us
C. Silva, A., Santos, D., Ferreira, D., & M. Lopes, C. (2012). Lipid-based Nanocarriers As An
an
Alternative for Oral Delivery of Poorly Water- Soluble Drugs: Peroral and Mucosal Routes.
Chonn, A., & Cullis, P. R. (1995). Recent advances in liposomal drug-delivery systems. Current
e
Cipolla, D., Wu, H., Gonda, I., Eastman, S., Redelmeier, T., & Chan, H.-K. (2014). Modifying
ce
Davis, J. L., Paris, H. L., Beals, J. W., Binns, S. E., Giordano, G. R., Scalzo, R. L., Schweder, M.
M., Blair, E., & Bell, C. (2016). Liposomal-encapsulated Ascorbic Acid: Influence on
Dima, C., Assadpour, E., Dima, S., & Jafari, S. M. (2020). Bioavailability of nutraceuticals: Role
of the food matrix, processing conditions, the gastrointestinal tract, and nanodelivery
t
ip
https://doi.org/10.1111/1541-4337.12547
cr
Esfandyari, T., Camilleri, M., Ferber, I., Burton, D., Baxter, K., & Zinsmeister, A. R. (2006).
us
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in
https://doi.org/10.1080/00498254.2017.1350889
pt
Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A.,
ce
Forssen, E., Ross, M. E., & Levine, A. M. (1995). Phase I/II clinical and pharmacokinetic
Ac
https://doi.org/10.1200/JCO.1995.13.4.996
Gopi, S., Kargl, R., Kleinschek, K. S., Pius, A., & Thomas, S. (2018). Chitin nanowhisker –
Sreeraj, T. R., Divya, C., Kunnumakkara, A. B., & Stohs, S. J. (2017). Comparative Oral
1891. https://doi.org/10.1002/ptr.5931
Haham, M., Ish-Shalom, S., Nodelman, M., Duek, I., Segal, E., Kustanovich, M., & Livney, Y.
t
ip
D. (2012). Stability and bioavailability of vitamin D nanoencapsulated in casein micelles.
cr
Food and Function, 3(7), 737–744. https://doi.org/10.1039/c2fo10249h
us
Hakkimane, S. S., Shenoy, V. P., Gaonkar, S. L., Bairy, I., & Guru, B. R. (2018).
https://doi.org/10.2147/IJN.S163925
e d
Hemilä, H., & Chalker, E. (2020). Vitamin C may reduce the duration of mechanical ventilation
pt
https://doi.org/10.1186/s40560-020-0432-y
Ac
Hickey, S., Roberts, H. J., & Miller, N. J. (2008). Pharmacokinetics of oral vitamin C. Journal of
https://doi.org/10.1080/13590840802305423
IM, Z. M.-M. V., & 2003, undefined. (n.d.). Malvern instruments ltd.
Joseph, E., & Singhvi, G. (2019). Multifunctional nanocrystals for cancer therapy: a potential
nanocarrier. In Nanomaterials for Drug Delivery and Therapy (pp. 91–116). Elsevier.
https://doi.org/10.1016/b978-0-12-816505-8.00007-2
t
Jude, S., Amalraj, A., Kunnumakkara, A., Divya, C., Löffler, B.-M., & Gopi, S. (2018).
ip
Development of Validated Methods and Quantification of Curcuminoids and Curcumin
cr
Metabolites and Their Pharmacokinetic Study of Oral Administration of Complete Natural
us
Turmeric Formulation (CureitTM) in Human Plasma via UPLC/ESI-Q-TOF-MS
Katouzian, I., & Jafari, S. M. (2016). Nano-encapsulation as a promising approach for targeted
ce
delivery and controlled release of vitamins. In Trends in Food Science and Technology
Ac
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R.,
Park, J. B., Lazarev, A., Graumlich, J. F., King, J., & Cantilena, L. R. (1996). Vitamin C
Proceedings of the National Academy of Sciences of the United States of America, 93(8),
3704–3709. https://doi.org/10.1073/pnas.93.8.3704
Liu, N., & Park, H. J. (2010). Factors effect on the loading efficiency of Vitamin C loaded
https://doi.org/10.1016/j.colsurfb.2009.09.041
Liu, W., Tian, M., Kong, Y., Lu, J., Li, N., & Han, J. (2017). Multilayered vitamin C
application in mandarin juice. LWT - Food Science and Technology, 75, 608–615.
t
ip
https://doi.org/10.1016/j.lwt.2016.10.010
cr
Lopez-Toledano, M. A., Thorsteinsson, T., Daak, A. A., Maki, K. C., Johns, C., Rabinowicz, A.
us
L., & Sancilio, F. D. (2017). Minimal food effect for eicosapentaenoic acid and
Maione-Silva, L., de Castro, E. G., Nascimento, T. L., Cintra, E. R., Moreira, L. C., Cintra, B. A.
e
S., Valadares, M. C., & Lima, E. M. (2019). Ascorbic acid encapsulated into negatively
pt
charged liposomes exhibits increased skin permeation, retention and enhances collagen
ce
9
Ac
Maki, K. C., Palacios, O. M., Buggia, M. A., Trivedi, R., Dicklin, M. R., & Maki, C. E. (2018).
Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State. Clinical
Liposomes as vehicles for vitamins E and C: An alternative to fortify orange juice and offer
vitamin C protection after heat treatment. Food Research International, 44(9), 3039–3046.
https://doi.org/10.1016/j.foodres.2011.07.025
Mazidi, M., Rokni, H., Sahebkar, A. H., Mohammadi, A., Ghayour-Mobarhan, M., & Ferns, G.
A. (2016). Simvastatin treatment does not affect serum vitamin D concentrations in patients
t
ip
with dyslipidemia: A randomized double‑ blind placebo‑ controlled cross‑ over trial.
cr
International Journal of Preventive Medicine, 2016(June). https://doi.org/10.4103/2008-
us
7802.183652
Mikirova, N., Casciari, J., & Hunninghake, R. (2019). Continuous intravenous Vitamin C in the
an
cancer treatment: Reevaluation of a phase I clinical study. Functional Foods in Health and
M
Disease, 9(3), 180–204. https://doi.org/10.31989/ffhd.v9i3.590
d
Moghimipour, E., Rezaei, M., Ramezani, Z., Kouchak, M., Amini, M., Angali, K. A., Dorkoosh,
e
F. A., & Handali, S. (2018a). Folic acid-modified liposomal drug delivery strategy for
pt
174. https://doi.org/10.1016/j.ejps.2017.12.011
Ac
Moghimipour, E., Rezaei, M., Ramezani, Z., Kouchak, M., Amini, M., Angali, K. A., Dorkoosh,
F. A., & Handali, S. (2018b). Folic acid-modified liposomal drug delivery strategy for
174. https://doi.org/10.1016/j.ejps.2017.12.011
Nazarudheen, S., Dey, S., Kandhwal, K., Arora, R., Reyar, S., Khuroo, A. H., Monif, T., Madan,
S., & Arora, V. (2013). Combining benefits of an adrenergic and a muscarinic blocker in a
single formulation - A pharmacokinetic evaluation. Regulatory Toxicology and
Nedovic, V., Kalusevic, A., Manojlovic, V., Levic, S., & Bugarski, B. (2011). An overview of
https://doi.org/10.1016/j.profoo.2011.09.265
t
Nogueira, E., Gomes, A. C., Preto, A., & Cavaco-Paulo, A. (2015). Design of liposomal
ip
formulations for cell targeting. In Colloids and Surfaces B: Biointerfaces (Vol. 136, pp.
cr
514–526). Elsevier. https://doi.org/10.1016/j.colsurfb.2015.09.034
us
Pereira, S., Egbu, R., Jannati, G., & Al-Jamal, W. T. (2016). Docetaxel-loaded liposomes: The
an
effect of lipid composition and purification on drug encapsulation and in vitro toxicity.
Pignatello, R., Ricupero, N., Bucolo, C., Maugeri, F., Maltese, A., & Puglisi, G. (2006).
e
Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery
pt
Rogers, J. A., & Anderson, K. E. (1998). The potential of liposomes in oral drug delivery. In
Ac
Critical Reviews in Therapeutic Drug Carrier Systems (Vol. 15, Issue 5, pp. 421–480).
Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000). Long-term efficacy and safety of
Roy, S. M., Sahoo, S., & Vallabhbhai, S. (2015). Controlled Drug Delivery: Polymeric
Biomaterials for One Pot Synthesis and Antioxidant Activity of Sulfonyl Hydrazones of
120050023
t
ip
Sánchez-Lara, K., Turcott, J. G., Juárez-Hernández, E., Nuñez-Valencia, C., Villanueva, G.,
cr
Guevara, P., De la Torre-Vallejo, M., Mohar, A., & Arrieta, O. (2014). Effects of an oral
us
nutritional supplement containing eicosapentaenoic acid on nutritional and clinical
outcomes in patients with advanced non-small cell lung cancer: RANDOMISED trial.
an
Clinical Nutrition, 33(6), 1017–1023. https://doi.org/10.1016/j.clnu.2014.03.006
M
Saravanan, V. (2014). An open-label, balanced, randomized, two-treatment, two-period, two
d
Sharma, A., & Sharma, U. S. (1997). international journal of pharmaceutics Review Liposomes
ce
154).
Tippabhotla, S. K., Thota, S., Khan, S. M., Gadiko, C., Yergude, S., Cheerla, R., Nakkawar, M.,
Betha, M. R., Battula, R., & Vobalaboina, V. (2013). Pharmacokinetics of two formulations
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012).
Tohen, M., Jacobs, T. G., Grundy, S. L., McElroy, S. L., Banov, M. C., Janicak, P. G., Sanger,
t
T., Risser, R., Zhang, F., Toma, V., Francis, J., Tollefson, G. D., & Breier, A. (2000).
ip
Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study.
cr
Archives of General Psychiatry, 57(9), 841–849. https://doi.org/10.1001/archpsyc.57.9.841
us
Van der Velden, U. (2020). Vitamin C and Its Role in Periodontal Diseases - The Past and the
an
Present: A Narrative Review. Oral Health & Preventive Dentistry, 18(2), 115–124.
https://doi.org/10.3290/j.ohpd.a44306
M
Wijetunge, S. S., Wen, J., Yeh, C. K., & Sun, Y. (2020). Wheat germ agglutinin liposomes with
d
https://doi.org/10.1016/j.colsurfb.2019.110572
ce
Wu, X., Kasselouri, A., Vergnaud-Gauduchon, J., & Rosilio, V. (2020). Assessment of various
Ac
https://doi.org/10.1016/j.ijpharm.2020.119168